Evaluation od Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk (Omega)

  • STATUS
    Recruiting
  • End date
    Nov 17, 2023
  • participants needed
    150
  • sponsor
    Eclipse Medical Ltd.
Send
Updated on 6 April 2022
See if I qualify

Summary

The purpose of the study is to assess the safety and performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in LAA (Left Atrial Appendage) closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk.

Description

Omega™ LAA (Left Atrial Appendage) Occluder used in combination with the indicated Omega™ Delivery System is a permanent implant to the left atrial appendage for percutaneous insertion. LLA (Left Atrial Appendage) occlusion appears to be a feasible option for stroke reduction in AF patients at high risk for stroke, who are contraindicated for anticoagulation or who suffered a stroke despite OC. This study will evaluate safety and performance, using a study design which is based on inputs from pre-clinical testing, the risk analysis and data available from other LAA (Left Atrial Appendage) devices.

Details
Condition Non-Valvular Atrial Fibrillation
Treatment Omega™LAA Occluder implantation
Clinical Study IdentifierNCT04829929
SponsorEclipse Medical Ltd.
Last Modified on6 April 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

18 years of age or older
Documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF)
At increased risk of stroke or systemic embolism defined as CHADS2 score (Risk of Stroke with AF". VA Palo Alto Medical Center and at Stanford University: the Sportsmedicine Program and the Cardiomyopathy Clinic: Congestive/Hypertension/Age/Diabetes/Stroke): ≥ 2 or a CHA2DS2-VASc score (Congestive/Hypertension/Age/Diabetes/Stroke/Vascular disease/Sex) ≥ 3
Deemed, by investigator, to be unsuitable or contraindicated for long term oral anticoagulation therapy due to high bleeding risk
To have suitable anatomy for percutaneous Left Atrial Appendage occlusion procedure with a single Omega™ device
Able and willing to comply with the required medication regimen post-device implant
Able to understand and willing to provide written informed consent to participate in the study
Able to and willing to return for required follow-up visits and examinations

Exclusion Criteria

Requires long-term oral anticoagulation therapy for any indication other than atrial fibrillation
Contraindicated for or allergic to aspirin/clopidogrel, warfarin or novel oral anticoagulant (NOAC) use
Implanted with a mechanical heart valve prosthesis thus requiring long term oral anticoagulation
Has any contraindications for a percutaneous catheterization procedure (e.g. subject is too small to accommodate the transoesophageal echocardiogram (TEE/TOE) probe or required catheters, or subject has active infection or bleeding disorder)
Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment per physician discretion)
Stroke or transient ischemic attack (TIA) within 6 weeks prior to implant procedure
Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure
Myocardial infarction (MI) within 90 days prior to implant
New York Heart Association Class IV Congestive Heart Failure
Left ventricular ejection Fraction (LVEF) ≤ 30%
Reversible cause of AF (i.e. secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
Left atrial appendage is obliterated or surgically ligated
Resting heart rate >110 bpm
Thrombocytopenia (defined as < 70,000 platelets/mm3) or anaemia with haemoglobin concentration of < 10 g/dl (i.e. anaemia as determined by the investigator which would require transfusion)
Actively enrolled or plans to enrol in a concurrent clinical study in which the active treatment arm may confound the results of this trial
Active endocarditis or other infection producing bacteraemia
Subject has a known malignancy or other illness where life expectancy is less than 2 years
Impaired renal function with eGFR (Estimated Glomerular Filtration Rate) <40 ml/min/1.73 m2
More than mild hepatic failure, i.e. ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), or Alkalic Phosphatase >2× upper limit of normal
Echocardiographic Exclusion Criteria
Intracardiac thrombus - including Left Atrial Appendage - visualized by echocardiographic imaging
Existing circumferential pericardial effusion >2mm
Significant mitral valve stenosis (i.e. mitral valve area <1.5 cm2)
High risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (atrial septal excursion >15mm; excursion defined as maximal protrusion of the ASA (Atrial Septal Aneurysm) beyond the plane of the atrial septum during cardiac cycle) or large shunt (substantial passage of bubbles, i.e. ≥ 25, within 3 cardiac cycles from appearing in the right atrium)
Complex atheroma with mobile plaque of the descending aorta and/or aortic arch
Cardiac tumour
Left Atrial Appendage anatomy cannot accommodate an Omega™ device (as per IFU)
Placement of the device would interfere with any intracardiac or intravascular structure
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note